Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ASTX727 · 1 trial · 1 indication
Per CTCAE 5.0
| Arm | Type | Description |
|---|---|---|
| ASTX727 + itacitinib | EXPERIMENTAL | ASTX727 and itacitinib will be taken by mouth |
| ASTX727 + ruxolitinib | EXPERIMENTAL | ASTX727 and ruxolitinib will be taken by mouth |
| Name | Type | Description |
|---|---|---|
| ASTX727 | DRUG | Taken by mouth daily during days 1-5 of every 28-day cycle. |
| Itacitinib | DRUG | Taken by mouth daily during each 28-day cycle |
| Ruxolitinib | DRUG | Dosage will be 5,15, or 20mg Taken by mouth BID for 28-day cycle |
Inclusion Criteria: 1. Must be ≥ 18 years of age at the time of signing the Informed Consent Form (ICF); must voluntarily sign an ICF; and must be willing and able to meet all study requirements. 2. Must have morphologically confirmed diagnosis of MDS/MPN, excluding JMML, in accordance with WHO (20...
ASTX727 is an investigational small molecule being studied for the treatment of myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN), a group of blood cancers. It is currently in Phase 1 clinical development and has not been approved by the FDA.
ASTX727 is being developed by Incyte Corporation (NASDAQ: INCY). The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with MDS/MPN overlap syndromes.
ASTX727 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is actively recruiting participants in the United States.
ASTX727 is being studied in a Phase 1 clinical trial with the identifier NCT04061421, titled "Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes (ABNL-MARRO)." The trial is recruiting 94 participants aged 18 years and older in the United States.
ASTX727 is a combination of decitabine and cedazuridine, which are the active ingredients in the drug. This combination is being studied for the treatment of MDS/MPN. The drug is also known by the code name ASTX727.